{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By KATIE THOMAS and ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}, {"rank": 2, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Valeant Pharmaceuticals announces major changes to its leadership, including resignations of chief executive J Michael Pearson and board member Howard B Schiller; also says it will restate its earnings and put activist shareholder William A Ackman on its board; shake-up offers signal firm is rethinking its performance-based environment.", "type_of_material": "News", "word_count": "1312", "lead_paragraph": "Valeant\u2019s chief will step down, one of many changes made by the drug maker, which faces a growing list of questions from investors and regulators.", "pub_date": "2016-03-22T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "A Shake-Up at Valeant Signals the End of an Era", "print_headline": "Shake-Up at Valeant Signals End of an Era"}, "snippet": "Valeant\u2019s chief will step down, one of many changes made by the drug maker, which faces a growing list of questions from investors and regulators.", "multimedia": [{"height": 126, "url": "images/2016/03/22/business/22valeant2/22valeant2-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/03/22/business/22valeant2/22valeant2-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 368, "url": "images/2016/03/22/business/22valeant2/22valeant2-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "368", "xlarge": "images/2016/03/22/business/22valeant2/22valeant2-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/03/22/business/22valeant2/22valeant2-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/03/22/business/22valeant2/22valeant2-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/03/22/business/valeant-ackman-pearson-earnings.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Pearson, John Michael (1959- )", "name": "persons"}, {"rank": "3", "is_major": "Y", "value": "Schiller, Howard B", "name": "persons"}, {"rank": "4", "is_major": "Y", "value": "Ackman, William A", "name": "persons"}, {"rank": "5", "is_major": "N", "value": "Appointments and Executive Changes", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Shareholder Rights and Activism", "name": "subject"}], "blog": [], "_id": "56eff71838f0d81c2692dd29", "source": "The New York Times"}